[{"id":"50d581ad-944c-4ed3-86ce-7d1ac402d2ae","acronym":"PC002-01","url":"https://clinicaltrials.gov/study/NCT05263583","created_at":"2022-03-02T16:52:44.847Z","updated_at":"2024-07-02T16:35:58.906Z","phase":"Phase 2","brief_title":"Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma","source_id_and_acronym":"NCT05263583 - PC002-01","lead_sponsor":"Cothera Bioscience, Inc","biomarkers":" MYC • BCL2","pipe":"","alterations":" ","tags":["MYC • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sepantronium bromide (PC-002)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 12/09/2022","start_date":" 12/09/2022","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 01/01/2024","study_completion_date":" 01/01/2024","last_update_posted":"2022-12-19"}]